Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Toxins (Basel) ; 12(9)2020 09 11.
Artículo en Inglés | MEDLINE | ID: mdl-32933013

RESUMEN

Pain is a distressful experience that can have a major impact on an individual's quality of life. The need for new and better analgesics has been further intensified in light of the current opioid epidemic. Substances obtained from amphibians have been shown to contain bioactive peptides that exert analgesic effects. The genus Phyllomedusa represents an important source of peptides and bioactive components. The aim of this study was to investigate the antinociceptive effects of the skin secretion of Phyllomedusa rohdei in rodent models of pain. The crude skin extract of P. rohdei was tested in different pain models: acetic acid-induced writhing test (mice), formalin test (rats), Von Frey electronic test for hypernociception induced by PGE2 (rats), and hot plate test (mice). Motor-impairing effects were tested using the rota-rod test. The results showed that the skin extract of P. rohdei exerted antinociceptive effects in all pain models tested. Particularly, the highest dose tested of the skin extract decreased acetic acid-induced writhing by 93%, completely blocked formalin-induced nociception both during the acute and inflammatory phases of the test, PGE2-induced hypernociception by 73% and increased latency to paw withdrawal in the hot plate test by 300%. The effects observed in the hot plate test were reversed by pretreatment with selective µ and κ, but not δ, opioid receptor antagonists, indicating a mechanism of action dependent on µ and κ opioid receptors. The results were not influenced by sedative effects. Further studies remain necessary to reveal the specific compounds involved in the antinociceptive effects of P. rohdei skin extract as a new therapeutic tool in pain management.


Asunto(s)
Analgésicos/farmacología , Anuros/metabolismo , Dolor Nociceptivo/prevención & control , Piel/metabolismo , Analgésicos/metabolismo , Animales , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Masculino , Ratones , Dolor Nociceptivo/etiología , Dolor Nociceptivo/metabolismo , Dolor Nociceptivo/fisiopatología , Umbral del Dolor/efectos de los fármacos , Ratas Wistar , Receptores Opioides delta/metabolismo , Receptores Opioides mu/metabolismo , Vías Secretoras
2.
PLoS One ; 15(6): e0234037, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32559185

RESUMEN

Psychobiotics correspond to a class of probiotics, mainly of the genus Lactobacillus and Bifidobacterium, capable of producing neuroactive substances, such as γ-aminobutyric acid (GABA) and serotonin, which exert effects on the brain-gut axis. Evidence suggests that psychobiotics can have a beneficial effect on mood, anxiety and cognition. The present study evaluated the effects of chronic administration of two new strains of Lactobacillus plantarum, L. plantarum 286 (Lp 286) and L. plantarum 81 (Lp 81) isolated from the fermentation of cocoa (Theobroma cacao L.) and cupuaçu (Theobroma grandiflorum), respectively, on cognitive, anxiety- and depressive-like behaviors in male Swiss mice. Different groups of animals were administered (oral gavage) solutions of vehicle (0.85% saline plus 15% skim milk), Lp 286 (109/0.1 ml CFU) or Lp 81 (109/0.1 ml CFU) for 30 days, and animals were tested for general locomotor activity, depressive-like behavior in the forced swim test, and learning/memory and anxiety-like behavior in the plus-maze discriminative avoidance task. Treatment with the strains Lp 286 and Lp 81 did not interfere with locomotor activity or learning and memory. The Lp 286 strain exerted anti-depressant- and anxiolytic-like effects under our experimental conditions. Our findings add to the current body of evidence suggesting that probiotics from the genus Lactobacillus may exert psychobiotic potential and introduce a new strain, Lp 286, as a potential candidate in the prevention or as therapeutic adjuvant in the treatment of mental disorders.


Asunto(s)
Ansiedad/microbiología , Conducta Animal , Cognición , Depresión/microbiología , Lactobacillus plantarum/fisiología , Animales , Locomoción , Masculino , Aprendizaje por Laberinto , Ratones
3.
Harv Rev Psychiatry ; 27(5): 279-289, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31385811

RESUMEN

LEARNING OBJECTIVES: After participating in this activity, learners should be better able to:• Assess the misuse potential of clonazepam• Characterize the nonmedical use of clonazepam• Identify the health problems associated with long-term use of clonazepam ABSTRACT: Clonazepam, a benzodiazepine, is commonly used in treating various conditions, including anxiety disorders and epileptic seizures. Due to its low price and easy availability, however, it has become a commonly misused medication, both in medical and recreational contexts. In this review, we aim to highlight the behavioral and pharmacological aspects of clonazepam and its history following its approval for human use. We examine the circumstances commonly associated with the nonmedical use of clonazepam and raise points of particular concern. Clonazepam, alone or in combination with other psychoactive substances, can lead to unwanted effects on health, such as motor and cognitive impairment, sleep disorders, and aggravation of mood and anxiety disorders. Prolonged use of clonazepam may lead to physical dependence and tolerance. There is therefore a need to find safer therapeutic alternatives for treating seizures and anxiety disorders. Greater awareness of its frequent nonmedical use is also needed to achieve safer overall use of this medication.


Asunto(s)
Trastornos de Ansiedad/tratamiento farmacológico , Clonazepam/uso terapéutico , Abuso de Medicamentos/psicología , Convulsiones/tratamiento farmacológico , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Clonazepam/efectos adversos , Disfunción Cognitiva/inducido químicamente , Quimioterapia Combinada/efectos adversos , Humanos , Trastornos del Humor/inducido químicamente , Trastornos Relacionados con Sustancias/etiología
4.
Sci Rep ; 8(1): 13837, 2018 09 14.
Artículo en Inglés | MEDLINE | ID: mdl-30218019

RESUMEN

Repeated nicotine administration has been associated with increased paradoxical sleep in rats and antinociceptive properties, whereas paradoxical sleep deprivation (PSD) elicits pronociceptive and inflammatory responses. Thus, we aimed to evaluate the effect of repeated nicotine administration and its withdrawal combined with PSD on pain sensitivity and inflammatory markers. Sixty adult male Wistar rats were subjected to repeated injections of saline (SAL) or nicotine (NIC) for 12 days or 7 days of nicotine followed by acute mecamylamine administration on day 8 to precipitate nicotine abstinence (ABST). On day 9, the animals were submitted to PSD for 72 h or remained in control condition (CTRL); on day 12, thermal pain threshold was assessed by the hot plate test. PSD significantly decreased the latency to paw withdrawal in all groups compared to their respective controls. ABST-PSD animals presented higher levels of interleukin (IL)-6 compared to all groups, except ABST-CTRL. After adjustment for weight loss, IL-6, IL-4 and tumor necrosis factor alpha, ABST-PSD was associated with the lowest pain threshold. Nicotine and IL-4 levels were predictors of higher pain threshold. Hyperalgesia induced by PSD prevailed over the antinociceptive action of nicotine, while the association between PSD and ABST synergistically increased IL-6 concentrations and decreased pain threshold.


Asunto(s)
Nicotina/efectos adversos , Umbral del Dolor/efectos de los fármacos , Privación de Sueño/fisiopatología , Animales , Hiperalgesia/complicaciones , Inmunidad/efectos de los fármacos , Interleucina-4/metabolismo , Interleucina-6/metabolismo , Masculino , Mecamilamina/farmacología , Nicotina/farmacología , Dolor/complicaciones , Dimensión del Dolor , Ratas , Ratas Wistar , Privación de Sueño/complicaciones , Privación de Sueño/metabolismo , Sueño REM/fisiología , Factor de Necrosis Tumoral alfa/metabolismo
5.
Pharmacol Biochem Behav ; 156: 16-23, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-28366798

RESUMEN

CB1 receptor antagonists have been shown to prevent acute and long-term behavioral effects of cocaine. Here we evaluate the effectiveness of the CB1 receptor antagonist rimonabant to modify sensitized responses to cocaine. Mice were treated with saline or cocaine injections in a 15-day intermittent sensitization treatment and subsequently treated with either vehicle, 1 or 10mg/kg rimonabant in the drug-associated environment for 8 consecutive days. Animals were then challenged with saline and cocaine in the open-field apparatus on subsequent days to evaluate the expression of conditioned and sensitized effects to cocaine. c-Fos protein expression was evaluated in the nucleus accumbens (NAcc), ventral tegmental area (VTA), basolateral amygdala (BLA), medial prefrontal cortex (mPFC) and caudate-putamen (CPu) after the last (cocaine) challenge. Previous treatment with 10mg/kg rimonabant blocked the expression of conditioned hyperlocomotion and behavioral sensitization to cocaine, but not acute cocaine-induced hyperlocomotion. These behavioral effects were accompanied by significant changes in c-Fos expression in the brain reward system. Chronic cocaine sensitization blunted a subsequent acute cocaine-induced increase in c-Fos protein in the NAcc, effect that was reversed by previous treatment with rimonabant. Treatment with 10mg/kg rimonabant also attenuated the significant increase in c-Fos expression in the CPu, mPFC and BLA induced by previous chronic sensitization with cocaine. Our findings add to the evidence that drugs targeting CB1 receptors are good candidates for the treatment of cocaine abuse and provide further insights into the mechanisms underlying endocannabinoid signaling within the brain reward system in the context of cocaine abuse.


Asunto(s)
Conducta Animal/efectos de los fármacos , Antagonistas de Receptores de Cannabinoides/farmacología , Cocaína/farmacología , Piperidinas/farmacología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Pirazoles/farmacología , Animales , Locomoción/efectos de los fármacos , Masculino , Ratones , Rimonabant
6.
Artículo en Inglés | MEDLINE | ID: mdl-24940169

RESUMEN

Juvenile idiopathic arthritis is a chronic disease that may lead to various consequences for patients and caregivers, especially in relation to sleep quality. Sleep is an essential process for homeostasis of the organism. In general, caregivers of children with JIA are more susceptible to these sleep disorders and a lower quality of life. This impairment in sleep can potentially affect the health of caregiver. For this reason, it is very important to continue to evaluate the quality of sleep in caregivers and how to support these JIA children's caregivers more effectively.


Asunto(s)
Artritis Juvenil/complicaciones , Cuidadores/psicología , Calidad de Vida , Trastornos del Sueño-Vigilia , Adolescente , Adulto , Niño , Disparidades en el Estado de Salud , Humanos , Trastornos del Sueño-Vigilia/etiología , Trastornos del Sueño-Vigilia/psicología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA